On the 25th, Samsung Bioepis announced that it has released the biosimilar of the autoimmune disease treatment Stelara (active ingredient ustekinumab) in the United States.
Stelara is an inflammatory autoimmune disease treatment developed by Johnson & Johnson's subsidiary, Janssen, for conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The annual global sales scale is $10.361 billion (15 trillion won), and the U.S. sales scale is $6.72 billion (10 trillion won).
The Stelara biosimilar 'PYZCHIVA' is an autoimmune disease treatment that inhibits the activity of cytokines, specifically interleukin (IL)-12 and IL-23, which are involved in inflammatory responses.
Samsung Bioepis released PYZCHIVA in the United States through its marketing partner, Sandoz. Sandoz is also responsible for sales in Europe, where the product was previously launched.
Linda Y. MacDonald, Deputy Minister of Samsung Bioepis, said, 'The launch of PYZCHIVA in the United States allows us to provide various treatment opportunities for patients with autoimmune diseases,' and noted, 'Expanding treatment options could reduce medical costs and ultimately contribute to a sustainable healthcare system.'